These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16038530)

  • 21. Low-dose warfarin prophylaxis for catheter-associated thrombosis in cancer patients. Can it be safely associated with 5-Fluorouracil-based chemotherapy?
    Magagnoli M; Castagna L; Masci G; Santoro A
    Oncologist; 2004; 9(5):594-5; author reply 596. PubMed ID: 15477645
    [No Abstract]   [Full Text] [Related]  

  • 22. [A woman with palmar and plantar hyperpigmentation].
    van Tienhoven G; Wilmink JW
    Ned Tijdschr Geneeskd; 2011; 155(45):A4100. PubMed ID: 22085578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database.
    Knudsen JF; Sokol GH
    Pharmacotherapy; 2008 Apr; 28(4):540-8. PubMed ID: 18363538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Capecitabine-induced severe hypertriglyceridemia: report of two cases.
    Kurt M; Babaoglu MO; Yasar U; Shorbagi A; Guler N
    Ann Pharmacother; 2006 Feb; 40(2):328-31. PubMed ID: 16391007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lethal toxicity of capecitabine due to abusive folic acid prescription?
    Clippe C; Freyer G; Milano G; Trillet-Lenoir V
    Clin Oncol (R Coll Radiol); 2003 Aug; 15(5):299-300. PubMed ID: 12924465
    [No Abstract]   [Full Text] [Related]  

  • 26. Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer.
    Saif MW; Wasif N
    JOP; 2008 Nov; 9(6):739-43. PubMed ID: 18981557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Onycholysis associated with capecitabine in patients with breast cancer.
    Hogeling M; Howard J; Kanigsberg N; Finkelstein H
    J Cutan Med Surg; 2008; 12(2):93-5. PubMed ID: 18346407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Experience with capecitabine in patients with anthracycline and/or taxane-resistant recurrent breast cancer].
    Tagaya N; Nakagawa A; Mori S; Tachibana M; Kakihara Y; Hamada K; Suzuki N; Kubota K
    Gan To Kagaku Ryoho; 2005 Aug; 32(8):1135-8. PubMed ID: 16121915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capecitabine induced colitis.
    Maggo G; Grover SC; Grin A
    Pathol Res Pract; 2014 Sep; 210(9):606-8. PubMed ID: 24947412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-Fluorouracil therapy.
    Davis DA; Fugate SE
    Pharmacotherapy; 2005 Mar; 25(3):442-7. PubMed ID: 15843293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer.
    Bell KA; Perna AG; Hsu S
    J Am Acad Dermatol; 2001 Nov; 45(5):790-1. PubMed ID: 11606938
    [No Abstract]   [Full Text] [Related]  

  • 32. Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer.
    Hata T; Kudo T; Sakai D; Takahashi H; Haraguchi N; Nishimura J; Hata T; Mizushima T; Yamamoto H; Doki Y; Mori M; Satoh T
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):389-96. PubMed ID: 27339150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor lysis syndrome following a single dose of capecitabine.
    Kurt M; Eren OO; Engin H; Güler N
    Ann Pharmacother; 2004 May; 38(5):902. PubMed ID: 15039470
    [No Abstract]   [Full Text] [Related]  

  • 34. Warfarin therapy: evolving strategies in anticoagulation.
    Horton JD; Bushwick BM
    Am Fam Physician; 1999 Feb; 59(3):635-46. PubMed ID: 10029789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
    Pierga JY; Fumoleau P; Brewer Y; Zelek L; Martin D; Turpin FL; Goudier MJ; Gil-Delgado M; Baticle JL; Namer M; Chollet P; Sutherland W; Barats JC;
    Breast Cancer Res Treat; 2004 Nov; 88(2):117-29. PubMed ID: 15564795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coronary artery spasm induced by capecitabine.
    Sestito A; Sgueglia GA; Pozzo C; Cassano A; Barone C; Crea F; Lanza GA
    J Cardiovasc Med (Hagerstown); 2006 Feb; 7(2):136-8. PubMed ID: 16645374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated international normalized ratio from vitamin K supplement discontinuation.
    Miesner AR; Sullivan TS
    Ann Pharmacother; 2011 Jan; 45(1):e2. PubMed ID: 21205949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of capecitabine-induced hyperpigmentation and radiation recall phenomenon.
    Ghosal N; Misra V
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):632. PubMed ID: 19304468
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A case of toxicity caused by drug interaction between capecitabine and phenytoin in patient with colorectal cancer].
    Sakurai M; Kawahara K; Ueda R; Fukui E; Yamada R
    Gan To Kagaku Ryoho; 2011 May; 38(5):841-3. PubMed ID: 21566450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.